{"id":26638,"date":"2012-04-20T06:42:07","date_gmt":"2012-04-20T10:42:07","guid":{"rendered":"http:\/\/asweetlife.org\/?p=26638"},"modified":"2015-12-29T08:53:08","modified_gmt":"2015-12-29T13:53:08","slug":"ultra-long-acting-insulin-degludec-reduces-nocturnal-hypoglycemia-new-studies-show","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=26638","title":{"rendered":"Ultra Long Acting Insulin Degludec Reduces Nocturnal Hypoglycemia, New Studies Show"},"content":{"rendered":"<div style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Novo-Nordisk-Logo1.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-26639 lazyload\" title=\"Novo Nordisk\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Novo-Nordisk-Logo1.png\" alt=\"Novo Nordisk\" width=\"215\" height=\"160\" \/><\/a><\/p>\n<p>Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compound from Novo Nordisk, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.<\/p>\n<p>The two studies included in total 1,635 participants and investigated insulin degludec compared to insulin glargine in a basal-bolus regimen in people with type 1 and type 2 diabetes. Both studies were \u2018treat-to-target\u2019 studies, meaning patient insulin doses were adjusted systematically to allow them to achieve a targeted fasting glucose level. As a result, patients successfully achieved comparable improvements in glucose control in both studies, allowing researchers to closely determine the differences in the rates of hypoglycemia.<\/p>\n<p>In type 2 patients, a significantly lower rate of overall hypoglycemic events was seen in the insulin degludec group, compared to those taking insulin glargine (11.1 vs. 13.6 episodes\/patient-year). In the type 1 diabetes group the rate of hypoglycemia was comparable between the two treatment arms.<\/p>\n<p>The rate of hypoglycemia at night was 25% lower in both type 1 and type 2 diabetes for patients treated with insulin degludec, compared to those taking insulin glargine (4.4 vs. 5.9 episodes\/patient-year and 1.4 vs. 1.8 episodes\/patient-year respectively).<\/p>\n<\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compound from Novo Nordisk, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.<br \/>\nThe two studies included in total 1,635 participants and investigated insulin degludec compared to insulin&#8230;<\/p>\n","protected":false},"author":131,"featured_media":26639,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[1257],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Degludec Ultra Long Acting Insulin Reduces Nocturnal Hypoglycemia, New Studies Show<\/title>\n<meta name=\"description\" content=\"Two new phase 3 studies show that ultra long acting insulin, Degludec, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=26638\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=26638\",\"url\":\"https:\/\/asweetlife.org\/?p=26638\",\"name\":\"Degludec Ultra Long Acting Insulin Reduces Nocturnal Hypoglycemia, New Studies Show\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=26638#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=26638#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Novo-Nordisk-Logo1.png\",\"datePublished\":\"2012-04-20T10:42:07+00:00\",\"dateModified\":\"2015-12-29T13:53:08+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Two new phase 3 studies show that ultra long acting insulin, Degludec, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=26638#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=26638\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=26638#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Novo-Nordisk-Logo1.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Novo-Nordisk-Logo1.png\",\"width\":215,\"height\":160,\"caption\":\"Novo Nordisk Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=26638#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ultra Long Acting Insulin Degludec Reduces Nocturnal Hypoglycemia, New Studies Show\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Degludec Ultra Long Acting Insulin Reduces Nocturnal Hypoglycemia, New Studies Show","description":"Two new phase 3 studies show that ultra long acting insulin, Degludec, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=26638","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=26638","url":"https:\/\/asweetlife.org\/?p=26638","name":"Degludec Ultra Long Acting Insulin Reduces Nocturnal Hypoglycemia, New Studies Show","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=26638#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=26638#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Novo-Nordisk-Logo1.png","datePublished":"2012-04-20T10:42:07+00:00","dateModified":"2015-12-29T13:53:08+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Two new phase 3 studies show that ultra long acting insulin, Degludec, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=26638#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=26638"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=26638#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Novo-Nordisk-Logo1.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/04\/Novo-Nordisk-Logo1.png","width":215,"height":160,"caption":"Novo Nordisk Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=26638#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Ultra Long Acting Insulin Degludec Reduces Nocturnal Hypoglycemia, New Studies Show"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/26638"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26638"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/26638\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/26639"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}